A Pharmacist may prescribe, according to OAR
855-115-0330 and OAR
855-115-0335, FDA-approved drugs
and devices listed in the following compendium, pursuant to a statewide drug
therapy management protocol.
(1)
Continuation of therapy including emergency refills of insulin and early
refills of opioid use disorder medications (v. 08/2024)
(2) Conditions
(a) Cough and cold symptom management
(A) Benzonatate (v. 06/2021);
(B) Short-acting beta agonists (v.
06/2021);
(C) Intranasal
corticosteroids (v. 06/2021);
(b) Vulvovaginal candidiasis (VVC) (v.
06/2021);
(c) COVID-19 Antigen
Self-Test (v. 12/2021);
(d)
SARS-CoV-2 Antiviral (v. 08/2024)
(3) Preventative care
(a) Emergency Contraception (v.
06/2021);
(b) Male and female
condoms (v. 06/2021);
(c) Tobacco
Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v.
06/2024);
(d) Travel Medications
(v. 06/2024);
(e) HIV Post-exposure
Prophylaxis (PEP) (v. 06/2023);
(f)
HIV Pre-exposure Prophylaxis (PrEP) (v.06/2023);
(g) Contraception (v. 06/2023);
(h) Sexually Transmitted Infections
Post-exposure Prophylaxis (STI PEP) (v. 06/2024);
(i) Short-acting Opioid Antagonists (v.
06/2024); and
(j) Vaccines:
(A) Standard Protocol for All Vaccines: Cover
Page & Assessment and Treatment Care Pathway (v. 06/2024);
(B) Standard Protocol for All Vaccines:
Managing Adverse Reactions (v. 06/2024);
(C) Cholera (v. 02/2024);
(D) Coronavirus 2019 (v. 12/2024);
(E) Haemophilus Influenza type b (v.
06/2024);
(F) Hepatitis A
containing vaccines (v. 02/2024);
(G) Hepatitis B containing vaccines (v.
02/2024);
(H) Human Papillomavirus
(v. 02/2024);
(I) Influenza -
Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2024-2025 (v.
12/2024);
(J) Influenza - Live
Attenuated Influenza Vaccine 2024-2025 (v. 12/2024);
(K) Japanese Encephalitis (v.
06/2024);
(L) Meningococcal
containing vaccines (v. 06/2024);
(M) Measles Mumps & Rubella containing
vaccines (v. 02/2024);
(N)
Pneumococcal (v. 06/2024);
(O)
Polio (v. 06/2024);
(P) Rabies (v.
02/2024);
(Q) Respiratory Syncytial
Virus (v. 12/2024);
(R) Tetanus
Diphtheria containing vaccines (v. 06/2024);
(S) Typhoid (v. 02/2024);
(T) Varicella containing vaccines (v.
02/2024);
(U) Yellow fever (v.
06/2024); and
(V) Zoster (v.
02/2024).
Notes
Or. Admin. Code
§
855-115-0345
BP
16-2023, adopt filed 08/16/2023, effective
3/1/2024;
BP
14-2024, temporary amend filed 03/01/2024, effective
3/1/2024 through 8/27/2024;
BP
25-2024, temporary amend filed 03/04/2024, effective
3/4/2024 through 8/30/2024;
BP
54-2024, amend filed 06/18/2024, effective
6/20/2024;
BP
61-2024, temporary amend filed 08/09/2024, effective
8/9/2024 through 2/4/2025;
BP
59-2024, amend filed 08/09/2024, effective
8/9/2024;
BP
66-2024, temporary amend filed 12/17/2024, effective
12/17/2024 through 6/14/2025;
BP
64-2024, amend filed 12/17/2024, effective
12/17/2024
Publications: Publications referenced are available from the
agency.
Statutory/Other Authority: ORS
689.205, 2024 HB 4002, 2024 SB
1506
Statutes/Other Implemented: ORS
689.645, ORS
689.649, ORS
689.689, 2024 HB 4002, 2024 SB
1506
